Analytical Data
-
Gene name
PCDHgA10
- Application
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q91XY9
-
Expression Region
Arg27~Thr265
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Research on the PCDHGA10 recombinant protein has gained significant attention due to its potential implications in neurobiology and cell adhesion mechanisms. Protocadherins, a subfamily of cadherin proteins, play critical roles in the establishment and maintenance of neural networks by mediating cell-cell interactions in the nervous system. PCDHGA10, a member of the clustered protocadherins, has been implicated in the regulation of neuronal differentiation and synapse formation. Studies suggest that alterations in the expression or function of PCDHGA10 may be associated with various neurological disorders, including autism spectrum disorders and schizophrenia. By producing and characterizing the recombinant form of PCDHGA10, researchers aim to elucidate its structural properties, binding affinities, and functional roles in neuronal contexts. These insights could provide valuable information for understanding the molecular basis of neurodevelopmental conditions and may pave the way for the development of therapeutic strategies targeting protocadherin pathways. Overall, the study of PCDHGA10 not only enhances our comprehension of cell adhesion in the brain but also contributes to the broader field of neurobiology and its associated disorders.
